ArticleFrontiers in oncology2026
Single-fraction stereotactic radiotherapy for lung malignancies: preliminary results of a mono-institutional experience.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The use of stereotactic body radiotherapy for primary and secondary lung lesions is well established. Although being supported by international guidelines, the application of single-fraction treatments is less reported in the literature. Methods: We report a mono-institutional, retrospective analysis of inoperable patients with small lung lesions-including both primary tumors and oligometastases-treated with single-fraction SBRT (SF-SBRT) via a helical tomotherapy linac. Although analyzed retrospectively, all data were prospectively collected. Acute and late toxicities were graded using CTCAE v5.0, while local control (LC), distant progression-free survival (DPFS), and overall survival (OS) were estimated via Kaplan-Meier and Cox regression models. Results: From August 2023 a total of 50 lung lesions in 49 patients. median age of 77 years (IQR, 72-80) received SF-SBRT. Thirty patients (61.2%) were male. Seven patients (14.3%) had a pacemaker or implantable cardioverter-defibrillator. Of the 50 treated lesions, 30 (60.0%) were primary NSCLC and 20 (40.0%) were pulmonary metastases, being colorectal cancer the most frequent non-pulmonary primary tumor. Most lesions were located in the right lung (62.0%) and in the upper lobe (64.0%). The median maximum tumour diameter was 1.9 cm (IQR, 1.6-2.4), and median prescription dose, for the entire cohort, was 27 Gy (IQR, 26-28), corresponding to a median BED Conclusions: In elderly patients with a significant burden of comorbidities presenting with isolated lung malignancies, single-fraction SBRT achieved remarkable metabolic responses alongside excellent short-term tolerance and survival. Despite the limitations of a small sample size and few events, these findings support the feasibility and biological effectiveness of single-fraction RT in selected frail subjects, warranting further prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.